Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,464 total articles
TG Therapeutics announced favorable Phase 1 trial results for their high-concentration subcutaneous formulation of BRIUMVI (ublituximab-xiiy), showing good tolerability, sustained drug exposure, and comparable biological activity versus intravenous administration. The data bolster confidence in the ongoing Phase 3 trial evaluating quarterly subcuta…
Palvella Therapeutics has completed a pre-New Drug Application meeting with the FDA for its investigational drug QTORIN™ rapamycin, aimed at treating microcystic lymphatic malformations, a serious and chronic vascular malformation with no current FDA-approved treatment. The company remains on track to submit its NDA in the second half of 2026 and p…
Celcuity Inc., a clinical-stage biotechnology company focused on targeted therapies for solid tumors, announced a proposed underwritten public offering of $400 million in convertible senior notes due 2032, with an option to increase by $60 million for over-allotments. Net proceeds will be used primarily to repay existing debt and for working capita…
GigaCloud Technology Inc, listed on Nasdaq as GCT, announced its inclusion in TIME's 'World’s Growth Leaders 2026' list, highlighting its strong multi-year revenue growth, financial stability, and market performance. The company is noted for its innovative B2B ecommerce platform that integrates technology, fulfillment, and marketplace ecosystems to…
Destination XL Group, Inc. announced that its board is reevaluating the previously announced merger with FullBeauty Brands due to a more challenging consumer environment and FullBeauty's indebtedness, considering the existing merger terms not in the best interests of DXL stockholders. The company remains committed to maximizing shareholder value an…
IREN Limited revealed plans for an 800MW data center campus in Bundey, South Australia, secured by a new high-voltage transmission connection. The project, set to begin energization by 2028, aims to support the rapidly growing AI infrastructure demand across the Asia-Pacific region. The campus leverages South Australia's target of 100% renewable en…
GXO Logistics has appointed Roberto Pascual as Managing Director for Spain and Portugal, aiming to intensify customer-centricity, accelerate vertical growth, and deploy advanced automation. Pascual brings over 25 years of contract logistics experience, previously serving as Managing Director at DHL Supply Chain Iberia. This leadership change follow…
FactSet announced that it will release its Q3 fiscal 2026 financial results on July 1, 2026, and will host a conference call to discuss the results along with a Q&A session. The company provides advanced financial data and analytics solutions to various sectors globally.
ScottsMiracle-Gro reaffirmed its fiscal 2026 financial guidance, citing approximately 1 percent growth in branded consumer point-of-sale dollars year-to-date and securing 90% of commodity costs to mitigate inflation. The company projects low single-digit U.S. consumer net sales growth, a gross margin of at least 32%, adjusted EBITDA growth, and fre…
SweetWater Brewing, the Southeast's leading craft beer brand and subsidiary of Tilray Brands (NASDAQ: TLRY), announced a citywide soccer celebration in Atlanta for summer 2026. Leveraging Atlanta hosting major international soccer matches, the program includes stadium activations, fan experiences, exclusive beer collaborations, and watch parties to…
FibroBiologics has dosed the first patients in its Phase 1/2 clinical trial of CYWC628, a topical allogeneic fibroblast-spheroid cell therapy designed to treat diabetic foot ulcers (DFUs). The multicenter, randomized study in Australia aims to evaluate safety, tolerability, and efficacy by comparing CYWC628 plus standard of care (SoC) against SoC a…
Axsome Therapeutics announced a settlement resolving all patent litigation related to its CNS disorder treatment SUNOSI (solriamfetol), allowing generic versions to enter the US market only after 2040 under specified conditions. This agreement removes ongoing legal uncertainties and reinforces Axsome's market exclusivity for SUNOSI in the US for ma…
Upstream Bio, a clinical-stage biopharmaceutical company focused on treatments for inflammatory and severe respiratory diseases, announced CEO Dr. Rand Sutherland will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company is currently advancing its lead candidate, verekitug, a mon…
Avalyn Pharma reported Q1 2026 financial results and key updates, highlighting progress in its inhaled therapy clinical trials for pulmonary fibrosis, including ongoing enrollment in its MIST Phase 2b and AURA Phase 2 trials and plans to initiate a Phase 1 trial for a combination therapy. The company successfully raised $345 million in an upsized I…
Cabaletta Bio announced encouraging clinical data for its investigational autologous CAR T cell therapy, rese-cel, showing durable, immunomodulator-free responses in patients with autoimmune diseases including dermatomyositis, systemic sclerosis, and lupus. The data support advancement in registrational studies and highlight potential for precondit…
Ovid Therapeutics Inc. has appointed Dr. Anna Greka, a distinguished physician-scientist and biotech innovator, to its Board of Directors. Dr. Greka will chair Ovid's new Science and Technology Committee and contribute to advancing Ovid's pipeline of targeted therapies for neurological and neuropsychiatric disorders, including epilepsy and KCC2 act…
Cocrystal Pharma Inc., a clinical-stage biotech company specializing in antiviral therapeutics, has named James Sapirstein as its new CEO effective immediately. Sapirstein brings extensive leadership experience in pharmaceutical development and commercialization, having led multiple product launches and held senior roles at major biopharma companie…
Ollie's Bargain Outlet Holdings, Inc. announced strong first quarter fiscal 2026 results with a 14.2% increase in net sales and 21.3% rise in adjusted earnings per share. The company opened 27 new stores, expanded its Ollie's Army loyalty base by 13%, improved gross margin to 41.9%, and returned $53 million to shareholders through share repurchases…
Destination XL Group, Inc. reported first quarter fiscal 2026 results with total sales declining 2.1% to $103.3 million and a net loss of $5.9 million compared to $1.9 million loss a year prior. The company is focused on strategic initiatives such as expanding its proprietary FiTMAP fit technology and leveraging AI to improve e-commerce discoverabi…
The Pennant Group, Inc. announced its acquisition and operational takeover of Memory Care of Contra Costa, a 46-unit senior living community in Pleasant Hill, California. This move marks Pennant's first senior living expansion in California since going public in 2019. The acquisition is structured as a triple net lease, reflecting Pennant's committ…
SOLOWIN HOLDINGS (Nasdaq: AXG) announced that its subsidiary AX Coin Bahrain has been licensed by the Central Bank of Bahrain to issue stablecoins under the country’s new regulatory framework. This milestone marks AX Coin as one of the first globally regulated stablecoin issuers under sovereign oversight, positioning the company to scale compliant …
Tenaya Therapeutics announced encouraging interim data from its MyPEAK-1 Phase 1b/2 clinical trial evaluating TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM). The treatment showed consistent improvements in cardiac remodeling, reduction of left ventricular hypertrophy, symptom relief, and increased exercise capacity acro…
Kura Oncology reported encouraging Phase 1a clinical trial results demonstrating darlifarnib combined with adagrasib yields objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in colorectal cancer patients with KRAS mutations. The company is launching a flexible platform study to explore multiple darlifa…
Taboola, a global leader in performance advertising technology, will be included in the Russell 3000 and Russell 2000 Indexes at the close of the June 2026 Russell Reconstitution. This inclusion reflects the company's strong business fundamentals and aims to enhance visibility among institutional investors, potentially supporting long-term sharehol…
Parsons Corporation secured a $28 million task order from the U.S. Air Force to provide comprehensive Field Site Support for the GARDEM 2 program. This award is part of multiple contracts won in 2026, bringing Parsons' total GARDEM-related awards to $218 million. Over five years, Parsons will deliver onsite training, system enhancements, testing, a…
